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peptides, Lebetins 1 and Lebetins 2. Despite the absence of Abstract Lebetins 1 and Lebetins 2, two polypeptide groups 
that inhibit platelet aggregation, were isolated from Vipera either RGD-related sequences or other sequences with known 
lebetina venom by gel filtration and reverse phase chromato- anti-aggregating activity, both groups displayed a strong in 
graphy. Amino acid sequencing indicated that the first group vitro antiplatelet activity and were able to prevent in vivo 
contains two major polypeptides of 13 and 12 residues; their collagen-induced thrombocytopenia in rats. 
molecular weight was determined by electrospray mass spectro- 
metry. The second was composed of two peptides of 38 and 37 2. Materials and methods 
residues, each with one disulfide bond. Sequence analysis 
revealed neither RGD sequence nor homology with other proteins 2.1. Materials 
including known snake or tick polypeptides. Lebetins 1 were Pro Venoms were obtained from mature Vipera lebetina (serpentarium 
and Lys rich peptides and their sequences were identical to the N- of the Institut Pasteur, Tunis) and stored at -20°C until use. Rabbits 
terminus of Lebetins 2. Lebetins inhibited platelet aggregation (HY/CR), Swiss mice and rats (Wistar) were from the Institut Pasteur 
induced by thrombin, collagen and PAF-acether. The 50% (Tunis). Human thrombin (R3235) was from Hoffmann La Roche 
Diagnostica (Basel, Switzerland), collagen and PAF-acether from concentration that inhibited human and rabbit platelet aggrega- Chronolog (Havertown, PA, USA), EGTA and ~-chymotrypsin 
tion induced by thrombin was 590 nM and 125 nM for Lebetins 1 from Sigma (St. Louis, MO, USA), fibrinogen from KabiVitrum 
and 100 nM and 8 nM for Lebetins 2, respectively. Lebetins 1 (Stockholm, Sweden), pentobarbital from Sanofi (Paris, France), se- 
and Lebetins 2 also inhibited fibrinogen-induced aggregation of quencing rade Arg C protease from Boehringer GmbH (Mannheim, 
ot-chymotrypsin-treated platelets as well as in vivo collagen- Germany). HPLC columns were from Beckman (Fullerton, CA, 
induced thrombocytopenia in rats with half effective doses of USA), Sephadex G-75 from Pharmacia (Uppsala, Sweden), the ag- 
2 nmol/kg and 4.2 nmol/kg, respectively. Lebetins were not toxic gregometer from Coultronics (Chronolog 560 CA; Margency, 
after intravenous injection into mice and rats. These polypeptides France), the 476 A sequencer f om Applied Biosystems Inc. (Foster 
form novel platelet inhibitors that could be used to delineate City, CA, USA), the amino acid analyzer from Beckman (Mo. 6300; 
further the mechanisms of platelet aggregation and serve as a Palo Alto, CA, USA). 
model for developing antithrombotic agents. 2.2. Purification of Lebetins 
A pool of venom (2 ml; 385 absorbance units at 280 nm) was gel- 
Key words: Aggregation; Antithrombotic; Platelet; Snake; filtered on a Sephadex G-75 column (2.6x 100 cm; flow rate: 16 ml/h; 
Thrombocytopenia; Venom fraction: 3 ml) in 200 mM ammonium acetate, pH 6.8. The fractions 
with anti-aggregation activity (determined as described below on 
thrombin-induced rabbit platelet aggregation) were further purified 
by analytical reverse phase HPLC on a C8 column (250x4.6 mm, 
5 ~tm) equilibrated in 5% acetonitrile/0.1% trifluoroacetic acid (TFA). 
1. Introduction Elution was performed using a linear gradient (5-70%) of acetonitrile/ 
0.1% TFA in 40 min (1 ml/min) and monitored by measuring the 
Several components isolated from snake venoms - e.g. absorbance (214 nm) with a Beckman 166 detector. The homogeneity 
platelet aggregation inhibitors, phospholipases and ADPases, of peptide fractions displaying anti-aggregation activity was checked 
on a C18 column (250x4.6 nun, 5 lam) in the conditions described 
thrombin-like nzymes, fibrinolytic enzymes affect hemosta- above. Venom proteins were quantified by the enhanced alkaline cop- 
sis by interfering with the coagulation and platelet aggrega- per ('Lowry') protein assay [9] and by absorbance at280 rim. Peptides 
tion processes [1-5]. Platelet aggregation involves a complex were quantified from amino acid composition. 
network of cell surface adhesion proteins, one of which is 
GPIIb/II Ia. GPI Ib/ I I Ia binds fibrinogen and this binding is 2.3. Protein analysis 
S-Pyridylethylated Lebetins 2 (10 nmol) were prepared by reduction 
inhibited by proteins isolated from snake venom and contain- of the disulfide bond with dithiothreitol (a 60-fold molar excess over 
ing an RGD sequence [1]: the 'disintegrins'. Fibrinogen- the S-S bond in 6 M guanidine, 250 mM Tris-HC1 pH 8.5, 4 mM 
GPIIb/ I I Ia interaction is the final step of a complex cascade EDTA, under nitrogen, at 40°C for 20 h in the dark) and S-alkylation 
of biochemical reactions [6] and cell morphological changes, by adding 4 vinylpyridine for 20 rain at 20°C. Alkylated and desalted 
Lebetins 2 (2 nmol) were digested with 2% (w/w) Arg C protease for 
including activation of platelets which become competent to 20 h in 100 mM Tris-HCl pH 7.6, 10 mM CaC12, at 37°C. The reac- 
bind fibrinogen, changes in shape, secretion of the granular tion was stopped by freezing. The resulting peptides were purified on a 
content and aggregation. These events are induced by platelet 140 HPLC system equipped with a C18 PTH column (2.1 X220 mrn, 
aggregation agonists [7,8] and each of these may be a target 5 Ixm, Applied Biosystems). After an initial isocratic step for 3 rain, a 
for anti-aggregation agents, gradient of 1.5 62% acetonitrile/0.1% TFA was applied for 60 min 
(flow rate: 200 [tl/min). Purified Lebetins 1 and Lebetins 2 were sub- 
We isolated from Vipera lebetina venom two groups of jected to Edman automated sequencing according to the manufac- 
turer's instructions. Amino acid analyses of native or alkylated pro- 
*Corresponding author. Fax: (33) 91 69 88 39. teins were performed after hydrolysis at ll0°C for 20 h or at 150°C 
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for 1 h in evacuated tubes. Electrospray mass spectrometry (ESMS) of Fractions II and particularly IV strongly inhibited throm- 
native Lebetins 1, and native or alkylated Lebetins 2 (5 gM in water/ bin-induced rabbit platelet aggregation. Characterization of 
methanol (50:50, v/v) containing 1% acetic acid) was performed on a 
VG-BIO-Q (Bio-tech)in the positive mode [10]. fraction II will be reported elsewhere. Here, we described 
the purification of fraction IV which contained low molecular 
2.4. Platelet preparation and in vitro aggregation assay weight peptides and represented 1%o of the absorbance of the 
Rabbit platelets were prepared from a 0.2 M EDTA-treated blood proteins in the crude venom. Fraction IV was investigated by 
sample [11]. Human platelets were prepared as in [12]: blood was 
collected in vials containing a sodium citrate/dextrose (1:5 v/v) mix- reverse phase HPLC on C8 column; five peaks were obtained 
ture after venipuncture of healthy volunteers free of drugs for at least (Fig. 1B is a typical run; n = 5). Two peaks with retention 
7 days. Platelets were resuspended in Tyrode's buffer pH 7.4 at a final times of 8.25 and 14.02 min were potent antiplatelet agents: 
concentration f 3 × l0 s cells/ml prior to the assay that was performed they were named Lebetins 1 and Lebetins 2, respectively. They 
at 37°C with stirring in an aggregometer. For anti-aggregation activity represented about 13% and 10% of the absorbance at 214 nm 
assays, washed platelets (1.2 × l0 s cells/400 gl) were incubated at 37°C 
for 2 min with Lebetins, and then stimulated with agonists (thrombin: of fraction IV. Lebetins 1 and Lebetins 2 appeared to be 
0.04 IU/ml; PAF acether: 10 -7 M; collagen: 5 gg/ml). The aggrega- homogeneous as judged by further analysis by C18 reverse 
tion was monitored by recording the change in light transmission. The phase HPLC (Fig. 1C,D). 
concentration of peptide (an average molecular weight was calculated 
for each peptide group and used thereafter in the study) giving 50% 
3.2. Protein analysis of  Lebetins inhibition of platelet aggregation (IC50) was determined from the lin- 
ear portion of the dose-response curve. N-terminal sequencing of native Lebetins 2 revealed two 
Rabbit platelets prepared as described above were treated with ct- homologous equences representing 80% (et) and 20% ([~) of 
chymotrypsin (8 IU/ml) for 15 min at 22°C [13] and then resuspended the total yield. The latter was deleted in the N-terminal part 
(3×10 s cells/ml). Human fibrinogen (0.125-1.5 mg/ml) was added by a Gly residue. The two sequences howed 4 gaps in each 
with or without Lebetins to the washed tx-chymotrypsin-treated plate- 
lets and the mixture was incubated for 7 min at 37°C with stirring. (Fig. 2Aa). Their molecular weights were determined by 
ESMS (Table 1) and were 3943.74+0.46 and 3886.92+0.38, 
2.5. In vivo inhibition of collagen-induced thrombocytopenia in rats the difference (56.82 + 0.84) being consistent with the absence 
This procedure was performed as in [14] with modifications. Rats of a Gly residue in [3. Assuming similar ionization states for 
(200 g) were anesthetized with sodium pentobarbital (1 mg/kg). Ca- 
theters were inserted into the jugular vein and the carotid. Lebetins these two homologous compounds [15], their relative amounts 
(0-50 gg/kg of body weight dissolved in 0.9% NaC1) were injected into estimated by ESMS agreed with proportions deduced from 
the left jugular. One minute later, 1 ml of blood was collected within sequencing. Reverse phase chromatography failed to separate 
30 s from the right carotid into a vial containing an EDTA (4.5 M)/ Lebetins 2et and 13 reduced and alkylated isoforms as they 
Tris (0.1 M)/indomethacin (0.15 M) pH 7.4 solution. Platelet rich differ only by a Gly residue. Complete primary structures 
plasma (PRP) was prepared by centrifugation (200×g, 10 min, 
22°C) and platelets were counted. Two minutes after the injection were deduced by sequencing the alkylated Lebetins 2et and 
of Lebetins, 1 mg of collagerdkg (a dose sufficient o lower the normal 13 and a C-terminal peptide (Fig. 2Ab,c) obtained by digestion 
platelet count by 60%) was injected into the left jugular vein. One with Arg C protease and elution from a microbore C18 col- 
minute later, 1 ml of blood was collected from the right carotid and umn (retention time = 28.24 min). The complete sequences of 
platelets were counted. Inhibition of the collagen-induced thrombocy- Lebetins 2et and [3 isoforms are shown in Fig. 2Ad,e. Each 
topenia was calculated by comparison of platelet counts observed in 
animals receiving Lebetins versus those receiving saline solution. The isoform was reticulated by one disulfide bond. These results 
effective doses giving 50% inhibition of thrombocytopenia (EDs0) are in agreement with those obtained by ESMS, for the native 
were calculated by linear regression of the linear portion of the as well as for the alkylated forms (Table 1). Native Lebetins 1 
dose-response curves, were also sequenced. Two major peptides, et and 13 (Fig. 2B), 
2.6. Toxicity and a minor one, y, were detected; et and 13 differed by a Gly 
Groups of six Swiss mice (20 + 2 g) were injected intravenously with residue at their N-terminus and represented 30 and 60% of 
50 ktg of Lebetins 1 or Lebetins 2 dissolved in saline solution pH 7.4. Lebetin 1 isoforms, respectively. Their molecular weights de- 
Toxicity was scored after 24 h. termined by ESMS were 1305.74 + 0.38 and 1248.69 + 0.31, 
respectively, and the difference (57.05+0.69) is consistent 
3. Results with an additional N-terminal Gly residue in Lebetin let 
(Fig. 2Bf). The calculated proportions deduced from ESMS 
3.1. Purification of  Lebetins measurements were 19% and 68%, respectively. There is a 
G-75 gel filtration of the crude venom yielded five protein good agreement between the calculated and the measured 
fractions. Fig. 1A shows a typical (n = 12) profile of the frac- masses and the relative amounts of Lebetins let and 13. A third 
tionated venom; the yield of the column was about 98%. minor isoform, Lebetin 1y (less than 10%), was detected. Le- 
Table 1 
Amino acid sequences and molecular masses of Lebetins 
Lebetin isoform Proposed sequence Form Calculated mass Measured mass 
Lebetin 2~ GDNKPPKKGPPNGCFGHKI- Native 3943.39 3943.74 + 0.46 
DRIGSHSGLGCNKVDDNKG 
Alkylated 4155.68 4156.61 _+ 0.77 
Lebetin 2[~ DNKPPKKGPPNGCFGHKI- Native 3886.33 3886.92 + 0.38 
DRIGSHSGLGCNKVDDNKG 
Alkylated 4098.63 4098.68 + 0.25 
Lebetin ltx GDNKPPKKGPPNG Native 1305.46 1305.74+0.38 
Lebetin 113 DNKPPKKGPPNG Native 1248.41 1248.69 + 0.31 
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Fig. 1. Purification of Lebetins. A: G-75 gel filtration of the venom (line). The fractions were assayed for inhibition of rabbit platelet aggrega- 
tion induced by thrombin: anti-aggregating units (U/ml) (e) were defined as 'absorbance at 280 nm per ml/IC~0'. B: Fraction IV was applied 
to a RP-HPLC C8 column. The fractions named Lebetins 1 (1C) and Lebetins 2 (1D) were further analyzed by a C18 column. 
betins la  and 13 were constituted by 13 and 12 amino acids 3.4. Inhibition by Lebetins of collagen-induced 
respectively, and Lebetins 2a and I~ by 38 and 37 amino acid thrombocytopenia in rats 
residues respectively. The amino acid composition analysis of Intravenous administration of Lebetins 1 and Lebetins 2 
Lebetins 1 and Lebetins 2 (data not shown) was in agreement inhibited collagen-induced thrombocytopenia with EDs0s of 
with their respective deduced sequences. Lebetins 1 are iden- 2.5 ~tg/kg (2 nmol/kg) and 17 ~tg/kg (4.2 nmol/kg), respec- 
tical to the N-terminal sequence of Lebetin 2 isoforms. Lebe- tively, in a representative experiment (n = 5). Doses of 20 
tins displayed no homology with known proteins, as deter- nmol/kg of Lebetins 1 and 13 nmol/kg of Lebetins 2 lowered 
mined by homology search in SwissProt, NBRF, PDB and the thrombocytopenia by 80-90% (Fig. 4). 
GenPro sequence data base. 
3.5. Toxicity 
3.3. In vitro platelet aggregation inhibition by Lebetins No toxicity was observed upon the intravenous injection of 
The crude venom of Vipera lebetina inhibited rabbit platelet Lebetins 1 and Lebetins 2 to mice. 
aggregation i duced by thrombin (0.04 IU/ml), PAF-acether 
(10 -7 M) or collagen (5 ~tg/ml) with comparable ICs0s (data 4. Discuss ion  
not shown; 70, 90 and 55 ~tg/ml, respectively, in a represen- 
tative experiment (n = 5)). Rabbit platelet aggregation i duced Vipera lebetina venom prevents the platelet aggregation i - 
by thrombin, PAF-acether or collagen was also inhibited by duced by various agonists, with ICsos between 55 and 90 ~tg/ 
Lebetins 1 with ICs0s of 125, 48 and 27 nM respectively (Fig. ml. Based on this observation, we isolated two polypeptide 
3A) and Lebetins 2 with ICs0s of 8, 48 and 5 nM, respectively groups that we named Lebetins 1 and Lebetins 2. The Lebe- 
(Fig. 3B). Lebetins 1 and Lebetins 2 also inhibited thrombin- tins preparations obtained by two successive reverse phase 
induced aggregation of human platelets with ICs0s of 590 nM HPLC steps appeared to be homogeneous. However, sequence 
and 100 nM, respectively (Fig. 3C). and ESMS analysis revealed that: 
Aggregation of a-chymotrypsin-treated platelets was also 1. Lebetins 2 contained two isoforms, a and 13, represent- 
achieved with fibrinogen; 1.5 mg/ml of fibrinogen induced ing respectively 80 and 20% of this group. They are 38 
50% of the maximum platelet aggregation i duced by throm- and 37 amino acid residues long, respectively. They con- 
bin and Lebetins 1 (115 nM) or Lebetins 2 (43 nM) lowered tain one disulfide bond and differ by a single Gly residue 
this aggregation by 50% (data not shown from a representa- present at the N-terminus of Lebetin 2cc This explains 
tive experiment; n--5), why they were not separated 
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5-8) sequence is identical to residues 109-112 of a derived cow 
A:LEBETINS2 K-casein undecapeptide [21], which inhibits ADP-induced 
platelet aggregation with an IC50 of about 100 ~tM. We ob- 
a GDNKPPKKGPPNG?F?HKIDRIGSH?GLG?NKVDDNK served here that Lebetins interfere with fibrinogen-induced 
DNKPPKKGPPNG?F?HKIDRIGSH?GLG?NKVDDNK aggregation but their mode of action remains entirely un- 
known: indeed, Lebetin-derived synthetic peptides do not in- 
b GDNKPPKKGPPNGCFGHKI DRIGSH ,~ A 
DNKPPKKGPPNGCFGHKIDRIGSHS ~'>0 ~ 100 
c IGSHSGLGCNKVDDNKG 
80 
d GDNKPPKKGPPNC-CFGHKI DRIGSHSGLGCNKVDDNKG (a) 
e DNKPPKKGPPNGCFGHKI DRIGSHSGLGCNKVDDNKG (~) ~ 60 
4o 
B: LEBET INS 1 .~ 
f GDNKPP~GPPSG (al ~ 20 
g DNKPPKKGPPNG ( ~ ) 
Fig. 2. Amino acid sequences of Lebetins. A: Sequences of Lebetins '~ 0 ,- 
2. a: native isoforms 0~ and [3; b: reduced and alkylated isoforrns a 0 200 400 600 800 
and 6; c: peptide (retention time: 28.24 min) obtained after Arg C 
proteolysis; d: deduced sequence of isoform a; e: deduced sequence Lebet ins  1 concent ra t ion  (nM)  
of isoform 6. B: Sequences of Lebetins 1. f: deduced sequence of 
isoform a; g: deduced sequence of isoform li 
.~ B 
,~  100 
2. the Lebetins 1 major isoforms a and ~l represented O ~
about 30% and 60% of this group. They are 13 and 12 ~ 80 
amino acid residues long, respectively. Their sequences 
t11  
are identical to the N-terminal sequences of Lebetins 2. ~. 
6O As observed for Lebetins 2, Lebetins 1 a and ~ differ by 
only a single Gly residue. These isoforms could perhaps 
be separated by anionic exchange chromatography, o 
Lebetins 1 might derive from Lebetins 2 by enzymatic lea- O~ 40 
vage. The nature of the processing and of the enzymes possi- 
bly involved needs to be delineated. The existence of a high .~ 20 
molecular weight anti-aggregating precursor cannot be ruled 
out since Sephadex G-75 fraction II of the venom contained ~ 0 
other antiplatelet aggregation compounds. These points are 0 50 100 150 
currently being investigated using antibodies directed against 
Lebetins 1 and Lebetins 2. Lebet ins  2 concent ra t ion  (nM)  
Lebetins 1 and Lebetins 2 inhibited rabbit and human 
platelet aggregation i duced by various agonists. Lebetins 2 --, 
were generally more active than Lebetins 1. The anti-aggregat- ~ 100 
ing activities of Lebetins are similar to those of snake RGD om ~ ~ C 
disintegrins [16-191 and tick non-RGD disaggregin [20], the ,~ 80 j~  
IC~0s of which range between 30 and 300 nM. However, Le- 
betins do not share significant sequence homology with these ~_ 
molecules or with any known protein. Lebetins are proline I~ 
and lysine rich peptides and the tetrapeptide PPKK (residues 
O 40 
o 
--" ~ 20 Fig. 3. Inhibition of platelet aggregation i  vitro by Lebetins. Rab- 
bit or human platelets were incubated with Lebetins for 2 min at 
37°C; agonists were then added (a representative experiment is "~ 
shown for each condition; n=5), A: Inhibition by Lebetins 1 of ~ 0 
rabbit platelet aggregation induced by thrombin (11), PAF-acether 0 1 2 3 
([3), or collagen (e). B: Inhibition by Lebetins 2 of rabbit platelet 
aggregation i duced by thrombin (11), PAF-acether ([3), or collagen Lebet ins  1 and Lebet ins  2 
(e). C: Inhibition by Lebetins 1 (0) and Lebetins 2 (©) of human concent ra t ion  (pM) 
platelet aggregation i duced by thrombin. 
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